annual meeting program - American Society of Clinical Oncology

SATURDAY
Saturday, June 5, 2010
Brd. 41F Outcome of patients (pts) with brain metastases (BMs) from HER2-positive
breast cancer (BC) treated with lapatinib plus capecitabine (LC). (Abstract
#1155)
G. Metro, J. Foglietta, L. Stocchi, M. Russillo, P. Papaldo, L. Crino, D. Giannarelli,
F. Cognetti, A. Fabi, S. Gori
Brd. 41G Dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (pts)
with metastatic breast carcinoma (MBC): A phase I/II study. (Abstract #1156)
M. N. Fornier, P. G. Morris, A. Abbruzzi, G. D’Andrea, T. Gilewski, J. Bromberg,
C. T. Dang, M. N. Dickler, L. Norton, C. Hudis
Brd. 41H Clinical characteristics, univariate, and multivariate Cox model analysis of
long-term (> 3 years) survivors of stage IV metastatic breast cancer treated
on phase II or III North Central Cancer Treatment Group (NCCTG) trials.
(Abstract #1157)
T. A. Patel, H. Liu, D. W. Hillman, A. C. Dueck, J. N. Ingle, V. Roy, T. J. Hobday,
D. W. Northfelt, E. A. Perez, North Central Cancer Treatment Group
168